Long-term modeling on HPV vaccination: do we really need any more?

Garattini, Livio; Curto, Alessandro; Vooren, Katelijne van de

doi:10.1586/14737167.2015.1023297

Cited by 4 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The quadrivalent vaccine further protects against types 6 and 11, which are responsible for around 90% of benign GWs and RRPs. Initially administered on a threedose schedule, since 2014 both vaccines have now been reduced to two doses for adolescents [9].…”

Section: Hpv Vaccinationmentioning

confidence: 99%

“…Since these unusually high prices might have been a major hurdle for vaccination programmes, many health authorities in Western European countries opted for competitive tenders including both vaccines. To account for the difference between the two vaccines in the preventions of GWs, a 'quality score' in favour of the quadrivalent vaccine is often added in tender clauses [9] so as not to consider only the best price offered.…”

Section: Hpv Vaccine Pricesmentioning

confidence: 99%

“…In fact, most of the published models have already been seen to be mere exercises in long-term forecasting [9], speculating on uncertain longterm 'trade-offs' to boost the chances of showing favourable results for vaccination [14][15][16]. Particularly when industry sponsored, these models may be considered exercises in marketing rather than science, mainly aimed at supporting prices held high on the basis of various heterogeneous assumptions and estimates open to the authors' discretion and manufacturers' influence [14]; these 'patchwork' analyses are eventually misleading and of scant utility for public policy purposes.…”

Section: Policy Implicationsmentioning

confidence: 99%

See 2 more Smart Citations

Pricing of HPV Vaccines in Europe: Back to the Future?

Garattini

Padula

2018

Appl Health Econ Health Policy

Self Cite

View full text Add to dashboard Cite

Section: Hpv Vaccinationmentioning

confidence: 99%

Section: Hpv Vaccine Pricesmentioning

confidence: 99%

Section: Policy Implicationsmentioning

confidence: 99%

See 1 more Smart Citation

Pricing of HPV Vaccines in Europe: Back to the Future?

Garattini

Padula

2018

Appl Health Econ Health Policy

Self Cite

View full text Add to dashboard Cite

“…At the time of their introduction, several health economic studies were conducted to predict the long-term effectiveness of HPV vaccination. However, these evaluations were based on short-term clinical data due to the limited number of years after the introduction of the vaccination [ 8 – 10 ].…”

Section: Introductionmentioning

confidence: 99%

“…By including factors such as herd immunity and potential cross-protection to other HPV types, these models could better capture the real-world effectiveness of HPV vaccines when it comes to long-term outcomes, such as prevention of CIN and cervical cancer. Moreover, current cost-effectiveness models often focus only on the benefits of cancer prevention [ 8 – 10 ], whereas CIN and corresponding treatment are also often associated with costs, negative side effects, and reduction in the quality of life.…”

Section: Introductionmentioning

confidence: 99%

An Updated Analysis of the Impact of HPV Vaccination Based on Long-term Effectiveness in the Netherlands

Luttjeboer

Simons

Westra³

et al. 2023

Infect Dis Ther

View full text Add to dashboard Cite

Introduction Vaccination against human papillomavirus (HPV) is considered the most effective strategy to protect women from cervical cancer. Three HPV vaccines are currently licensed in Europe and, although they are generally supported by favorable health economic outcomes, current models fall short in predicting vaccination benefits. Here, we aim to re-evaluate the health benefits of HPV vaccination, using updated long-term effectiveness data and emphasizing quality of life losses related to pre-cancer disease and treatment. Methods We used a static Markov model that compared “only screening” (includes unvaccinated girls) and “vaccination” (assumes 100% vaccination coverage with the bivalent HPV vaccine). A lifetime cohort of 100,000 uninfected 12-year-old girls was included, in which the number of cases with cervical intraepithelial neoplasia grade 2 or higher/3 (CIN2+, CIN3), cervical cancer, and cervical cancer deaths per scenario were determined. Furthermore, the reduction in major excisional procedures, the preterm deliveries averted, and the related gain in quality-adjusted life years (QALYs) due to vaccination were estimated. Results The bivalent vaccine showed larger reductions in CIN2+, CIN3, cervical cancer cases, cervical cancer deaths, and major excisional treatments, after including long-term efficacy and effectiveness data, compared to previous data. Moreover, we observed an increased amount of QALYs gained due to prevention of major excisional treatment and the negative side effects related to it. Conclusions Updated health economic models for HPV vaccination, using updated and long-term effectiveness data and including prevention of treatment-related side effects, demonstrate a substantial additional positive effect on vaccination outcomes. Indeed, extrapolation of the bivalent HPV vaccine’s updated long-term effectiveness data against HPV-related cervical diseases shows that the positive effects of vaccination may be more substantial than previously estimated. There is a graphical abstract available for this article. Graphical Abstract Supplementary Information The online version contains supplementary material available at 10.1007/s40121-023-00851-9.

show abstract

Public health value of universal HPV vaccination

Audisio

Icardi

Isidori

et al. 2016

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Highlights► Human Papillomavirus vaccination demands urgent attention. ► The cost-effectiveness of including boys into HPV vaccination programs should be re-assessed. ► Steps must be taken to achieve the target of universal vaccination. ► There is sufficient evidence to urge the EU Community to eradicate all HPV related cancers. ► Policymakers must consider effective vaccination programs in the prevention of cancers. AbstractBackground: The story of Human Papillomavirus vaccination demands reflection not only

show abstract

Long-term modeling on HPV vaccination: do we really need any more?

Cited by 4 publications

References 17 publications

Pricing of HPV Vaccines in Europe: Back to the Future?

Pricing of HPV Vaccines in Europe: Back to the Future?

An Updated Analysis of the Impact of HPV Vaccination Based on Long-term Effectiveness in the Netherlands

Public health value of universal HPV vaccination

Contact Info

Product

Resources

About